This is a preview of subscription content, log in via an institution to check access.
Reference
Barbaro D, et al. Low-intermediate dose of lenvatinib in anaplastic thyroid cancer is highly effective and safe. BMJ Case Reports 13: No. 12, 22 Dec 2020. Available from: URL: http://doi.org/10.1136/bcr-2020-236934
Rights and permissions
About this article
Cite this article
Ciclosporin/everolimus. Reactions Weekly 1843, 103 (2021). https://doi.org/10.1007/s40278-021-91205-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-021-91205-5